Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sudard P is an oral fixed-dose combination tablet containing the non-steroidal anti-inflammatory drug (NSAID) aceclofenac (100 mg) and the analgesic/antipyretic paracetamol (325 mg). Developed by Anglo-French Drugs & Industries, it is indicated for the symptomatic treatment of pain and inflammation associated with various musculoskeletal and joint disorders, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, cervical spondylitis, low-back pain, sprains, strains, and post-traumatic pain. Aceclofenac acts primarily as a selective inhibitor of cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, while paracetamol provides additional central analgesic and antipyretic effects by inhibiting prostaglandin synthesis in the central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aceclofenac + paracetamol (Anglo-French Drugs & Industries).